159 related articles for article (PubMed ID: 34118892)
21. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes.
Yen FS; Wei JC; Lin MC; Hsu CC; Hwu CM
BMC Endocr Disord; 2021 Feb; 21(1):25. PubMed ID: 33602190
[TBL] [Abstract][Full Text] [Related]
23. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
24. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.
Björkström K; Franzén S; Eliasson B; Miftaraj M; Gudbjörnsdottir S; Trolle-Lagerros Y; Svensson AM; Hagström H
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2769-2775.e4. PubMed ID: 31009793
[TBL] [Abstract][Full Text] [Related]
26. Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study.
Yen FS; Wei JC; Yu TS; Hsu CY; Hsu CC; Hwu CM
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429732
[TBL] [Abstract][Full Text] [Related]
27. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
28. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.
Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR
Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756
[TBL] [Abstract][Full Text] [Related]
29. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
[TBL] [Abstract][Full Text] [Related]
30. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Kasmari AJ; Welch A; Liu G; Leslie D; McGarrity T; Riley T
Am J Med; 2017 Jun; 130(6):746.e1-746.e7. PubMed ID: 28109969
[TBL] [Abstract][Full Text] [Related]
31. Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis.
Tseng CH
J Am Heart Assoc; 2019 Nov; 8(21):e011640. PubMed ID: 31630591
[TBL] [Abstract][Full Text] [Related]
32. Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients.
Saeed MJ; Olsen MA; Powderly WG; Presti RM
J Clin Gastroenterol; 2017 Jan; 51(1):70-76. PubMed ID: 27306942
[TBL] [Abstract][Full Text] [Related]
33. Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes.
Yen FS; Hsu CC; Hu KC; Hung YT; Hsu CY; Wei JC; Hwu CM
Int J Environ Res Public Health; 2022 Sep; 19(17):. PubMed ID: 36078769
[TBL] [Abstract][Full Text] [Related]
34. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Sep; 7(38):62687-62696. PubMed ID: 27409676
[TBL] [Abstract][Full Text] [Related]
35. Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
Makol A; Kanthaje S; Dhiman RK; Kalra N; Chawla YK; Chakraborti A
Exp Biol Med (Maywood); 2018 Feb; 243(4):323-326. PubMed ID: 29186978
[TBL] [Abstract][Full Text] [Related]
36. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.
Kaplan DE; Serper M; John BV; Tessiatore KM; Lerer R; Mehta R; Fox R; Aytaman A; Baytarian M; Hunt K; Albrecht J; Taddei TH;
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2148-2160.e14. PubMed ID: 32798709
[TBL] [Abstract][Full Text] [Related]
37. Indonesia Cohort of IO HAT Study to Evaluate Diabetes Management, Control, and Complications in Retrospective and Prospective Periods Among Insulin-Treated Patients with Type 1 and Type 2 Diabetes.
Rudijanto A; Saraswati MR; Yunir E; Kumala P; Puteri HH; Mandang VV
Acta Med Indones; 2018 Jan; 50(1):26-37. PubMed ID: 29686173
[TBL] [Abstract][Full Text] [Related]
38. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
39. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus.
Gentile S; Guarino G; Strollo F; Romano M; Genovese S; Masarone M; Ceriello A
Diabetes Res Clin Pract; 2016 Mar; 113():179-86. PubMed ID: 26803356
[TBL] [Abstract][Full Text] [Related]
40. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
